Zydus Lifesciences Gets U.S. FDA Nod To Produce Generic Prostate Cancer Drug
The drug will be produced at the group's manufacturing site in Moraiya, Ahmedabad, Zydus said.
Zydus Lifesciences R&D facility. (Source: Company website)
Zydus Lifesciences Ltd. on Saturday said it has received approval from the U.S. health regulator to produce generic prostate cancer treatment drug.
The company has received approval from the U.S. Food and Drug Administration to manufacture Enzalutamide capsules (40 mg), it said in a regulatory filing.
Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
The drug will be produced at the group's manufacturing site in Moraiya, Ahmedabad, Zydus said.
As per IQVIA MAT July 2024 data, Enzalutamide capsules (40 mg) had annual sales of USD 869.4 million in the U.S.
The group now has 400 approvals and has filed over 465 abbreviated new drug applications since the commencement of the filing process in FY 2003-04.
